Monitoring of NOAC Therapy: Standardizing Reference Intervals
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yiu Ming Bonaventure Ip, MRCP
- Phone Number: 852-35053856
- Email: iym984@ha.org.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Chinese University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ethnic Chinese ONLY
- 18 years old or above
- Non-valvular atrial fibrillation
- Duration of NOAC use at least 3 months
- No changes in NOAC dosage or type within 3 months
- Creatinine Clearance (by Cockcroft-Gault formula) >/=30mL/min
Exclusion Criteria:
- Valvular atrial fibrillation or no atrial fibrillation
- Recent haemorrhage or ischemia within 1 year
- Active liver disease
- Abnormal baseline clotting profile
- Abnormal baseline thrombocytopenia or thrombocytosis
- Thromboembolic tendency other than atrial fibrillation (e.g. antiphospholipid syndrome, protein C, S, anti-thrombin III deficiency)
- Non-compliant patients, defined as missing any doses of NOAC in recent 1 month
- Anticoagulation for disorders other than AF
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Ischemic stroke patient
Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NOAC level in blood
Time Frame: One week after the recruitment
|
The NOAC level in blood before and after the medication
|
One week after the recruitment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yiu Ming Bonaventure IP, MRCP, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Crec 2020.376
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.